Johns Hopkins Bloomberg School of Public Health (2026)
until then, the compound remains a subject of laboratory investigation, supplied strictly for research use only
However, the clinical relevance of these findings in the context of MC4R deficiency remains to be fully explored in larger animal models and human trials
[Greger then walks through the package inserts for Wegovy (high-dose semaglutide) and Zepbound (tirzepatide), listing thyroid-tumour warnings, pancreatitis, gall-bladder disease, risk of hypoglycaemia when combined with other agents, kidney injury, allergic reactions, diabetic retinopathy worsening, raised heart-rate, and suicidal thoughts or behaviours.] Suicide risk (the good news segment)
Will I need to pass a federal background investigation